GenAI，代謝重程式設計和空間組學攻破癌症困難

神農智慧製藥是一家屢獲殊榮的初創公司，作為首個生成式AI和空間組學加代謝重程式設計賦能的治癌抗衰療法研發平臺，致力研發Best-in-Class靶點及藥物，解決人類未來老齡化的社會問題。神農智慧製藥融入全球視野，在多個前沿技術領域取得了重要突破，發表超過42篇國際頂刊文章，擁有8項國際專利和8項國際科技創新大賽獎項。

How will the project address global tensions, especially between the US and China? Also, the funding goal seems too low compared to the ambitious project scope.

The project focuses on drug pipelines rather than CRO services. It aims to address a common global goal. The team has multinational collaborators from the UK, China (including Hong Kong and mainland), and the US.

Why was the presentation not broadcasted to other participants? Also, how does the company handle IP issues, especially since AI is generally not recognized as an inventor in patent applications?

The presentation wasn't broadcasted because the patent is under application. The drug in question is a repurposed drug, and the team is applying for extended safeguards. They have confidential collaborations with CONBA. Regarding IP, the team's expertise in using AI algorithms is their most valuable IP. They are developers with both pharma and AI expertise.

What is the business model? Is the platform being sold, used as a subscription model, or provided as a service? Also, how does it compare to existing AI models like those from Silicon Medicine?

The business model focuses on in-house pipelines that the team plans to license out in the next 3-4 years. They provide services by analyzing and giving insights. The platform differentiates itself from existing ones because it combines AI with pharmaceutical expertise, unlike first-generation AI drug startups that rely solely on AI.